Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders
Journal of Bone Metabolism · 30.11.2025 · 32 (4) · 263-275
DOI: 10.11005/jbm.25.919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone Metabolism, erschienen am 30.11.2025. Verfasst von Jongmin Baik und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Korea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Glucagon-like peptide-1 (GLP-1) analogs, originally developed as antidiabetic agents, have emerged as groundbreaking drugs for treating obesity, following reports of their remarkable weight-reducing effects. With growing recognition of obesity as a disease in modern society and a sharp rise in its prevalence, pharmacological interventions are now being actively pursued. However, due to their mechanism of action, primarily appetite suppression, GLP-1 analogs have been associated with various adverse effects. Most notably, muscle loss — which may be related to reduced nutritional intake — has become an important issue in the long-term management of patients undergoing GLP-1 therapy. This has drawn attention to myostatin (MSTN) inhibitors for their ability to significantly increase muscle mass. These agents are now being explored not only as a strategy to offset the side effects of GLP-1 analogs, but also as direct therapeutics for a range of metabolic disorders, including obesity and diabetes. In this review, we discuss the emerging therapeutic potential of MSTN inhibitors and examine current clinical trials investigating their use alone or in combination with GLP-1 analogs in metabolic disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Genetics, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Korea.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Baik, J., & Lee, Y. S. (2025). Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders. Journal of Bone Metabolism, 32(4), 263-275. https://doi.org/10.11005/jbm.25.919
Vancouver
Baik J, Lee YS. Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders. Journal of Bone Metabolism. 2025;32(4):263-275. doi:10.11005/jbm.25.919
BibTeX
@article{Baik2025,
author = {Baik, Jongmin and Lee, Yun-Sil},
title = {Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders},
journal = {Journal of Bone Metabolism},
year = {2025},
volume = {32},
number = {4},
pages = {263--275},
doi = {10.11005/jbm.25.919}
}
EUVIMED